Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Heron Therapeutics (HRTX)
NASDAQ:HRTX
Holding HRTX?
Track your performance easily
HRTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.50 - $3.93
Previous Close$1.8
Volume1.21M
Average Volume (3M)1.85M
Market Cap
$273.00M
Enterprise Value$384.37M
Total Cash (Recent Filing)$67.35M
Total Debt (Recent Filing)$178.71M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Nov 12, 2024EPS Estimate
-$0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding151,668,017
10 Day Avg. Volume1,367,647
30 Day Avg. Volume1,848,966
Standard Deviation0.27
R-Squared0.12
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-7.08
Price to Sales (P/S)2.00
Price to Cash Flow (P/CF)-14.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.82
Enterprise Value/Gross Profit6.21
Enterprise Value/Ebitda-9.48
Forecast
1Y Price Target
$7.00Price Target Upside295.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Heron Therapeutics News
PremiumCompany Announcements
Heron Therapeutics Strengthens Leadership with New Board Appointment
PremiumPre-Earnings
Is HRTX a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Partnership GrowthProgress with deployment of the CrossLink partnership and ongoing launch of Aponvie point to growth acceleration.
Product InnovationFDA approved HRTX's application for a new product presentation of Zynrelef that includes a vial access needle (VAN).
Profitability OutlookAdvancement towards near-term profitability, starting with positive adjusted EBITDA.
Bears Say
EarningsFollowing the second quarter earnings, there is weakness due to a slight miss on top-line performance, causing investor focus to shift towards quarterly numbers and the company's progress towards profitability.
Financial PerformanceThe overall top-line performance in the second quarter is considered unmemorable, raising concerns about the company's financial growth.
LitigationA significant upcoming concern is the decision on the Cinvanti patent infringement lawsuit, which is anticipated to impact the company's future by the end of 2024.
---
Ownership Overview
5.21% Insiders
11.70% Mutual Funds
2.92% Other Institutional Investors
70.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HRTX FAQ
What was Heron Therapeutics’s price range in the past 12 months?
Heron Therapeutics lowest stock price was $0.50 and its highest was $3.93 in the past 12 months.
What is Heron Therapeutics’s market cap?
Currently, no data Available
When is Heron Therapeutics’s upcoming earnings report date?
Heron Therapeutics’s upcoming earnings report date is Nov 12, 2024 which is in 4 days.
How were Heron Therapeutics’s earnings last quarter?
Heron Therapeutics released its earnings results on Aug 06, 2024. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.039 by -$0.021.
Is Heron Therapeutics overvalued?
According to Wall Street analysts Heron Therapeutics’s price is currently Undervalued.
Does Heron Therapeutics pay dividends?
Heron Therapeutics does not currently pay dividends.
What is Heron Therapeutics’s EPS estimate?
Heron Therapeutics’s EPS estimate is -$0.04.
How many shares outstanding does Heron Therapeutics have?
Heron Therapeutics has 151,668,010 shares outstanding.
What happened to Heron Therapeutics’s price movement after its last earnings report?
Heron Therapeutics reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.039. Following the earnings report the stock price went down -25.094%.
Which hedge fund is a major shareholder of Heron Therapeutics?
Among the largest hedge funds holding Heron Therapeutics’s share is Caxton Associates LP. It holds Heron Therapeutics’s shares valued at 708K.
---
Heron Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (295.48% Upside)
$7.00 (295.48% Upside)
Blogger Sentiment
Bullish
HRTX Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 236.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
143.24%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.40%
Trailing 12-Months
Company Description
Heron Therapeutics
Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bio erodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA.
---
HRTX Company Deck
---
HRTX Earnings Call
Q2 2024
0:00 / 0:00
---
HRTX Stock 12 Month Forecast
Average Price Target
$7.00
▲(295.48% Upside)
Technical Analysis
Best Analysts Covering HRTX
1 Year
1 Year Success Rate
13/46 ratings generated profit
1 Year Average Return
-3.72%
reiterated a buy rating 12 months ago
Copying Boris Peaker's trades and holding each position for 1 Year would result in 28.26% of your transactions generating a profit, with an average return of -3.72% per trade.
---